Lycia Therapeutics Prices $318M IPO, Shares Rise in Debut
Protein degrader developer Lycia Therapeutics priced an upsized IPO of about 17.64 million shares at $18 each, raising roughly $318 million, and its stock rose in its trading debut.
2newsrooms
2articles
15 hoursrunning
Oct 22first seen
Ask Scout
Scout answers questions about this story using only the coverage below.
Coverage over time
Articles
| Oct 23, 9:57 AM | qz.com | Lycia Therapeutics stock surges in IPO debut after pricing about $317.5M offering |
| Oct 22, 6:37 PM | biopharmadive.com | Protein degrader specialist Lycia prices $318M IPO |